



Summary of Safety and Clinical Performance (SSCP)

This Summary of Safety and Clinical Performance (SSCP) is intended to provide public access to an updated summary of the main aspects of the safety and clinical performance of the HepaSphere Microspheres.

The SSCP is not intended to replace the instructions for use as the main document to ensure the safe use of the HepaSphere Microspheres, nor to provide diagnostic or therapeutic suggestions to intended users or patients.

The English version of this SSCP document (SSCP0002) has been validated by the notified body. The following information is intended for users/healthcare professionals. A more general information summary is provided for patients and lay persons.

**1.0 Device identification and general information**

HepaSphere Microspheres were first CE-marked by Biosphere Medical in 2004 for the embolization of hepatocellular carcinoma and metastases to the liver. Chemoembolization with HepaSphere Microspheres loaded with doxorubicin for hepatocellular carcinoma and metastases to the liver received CE-mark in 2007. More recently, HepaSphere Microspheres loaded with irinotecan has been approved for embolization of metastatic colorectal cancer (mCRC) to the liver (CE-mark in 2015).

1.1 Device trade name:

The device trade name is HepaSphere® Microspheres, and the model numbers covered by this SSCP are presented in Table 1.

Table 1. Devices Included in this Summary of Safety and Clinical Performance

| Nominal dry size (µm) | Size after Reconstitution (µm) | Colour code | Reference code by weight | |
|--------------------------|-----------------------------------|-------------|--------------------------|------------|
| | | | 25 mg vial | 50 mg vial |
| 20-40* | 80-160 | Grey* | V125HS* | V150HS* |
| 30-60 | 120-240 | Orange | V225HS | V250HS |
| 50-100 | 200-400 | Yellow | V325HS | V350HS |
| 100-150 | 400-600 | Blue | V525HS | V550HS |
| 150-200 | 600-800 | Red | V725HS | V750HS |

*HepaSphere Q2 Microspheres is also a brand name of the 20-40µm size range

1.2 Manufacturer Information

The name and address of the manufacturer of the HepaSphere Microspheres are provided in Table 2.

Table 2. Manufacturer Information

| Manufacturer Name | Address of Manufacturer |
|------------------------|--|
| Biosphere Medical S.A. | Parc des Nations – Paris Nord II, 383 Rue de la Belle Etoile, 95700 Roissy en France, FRANCE |

1.3 Manufacturer Single Registration Number (SRN)

The Single Registration Number for the manufacturer is included in Table 3 and Table 4.

**1.4 Basic UDI-DI**

The basic Unique Device Identifier (UDI) with Device Identification (DI) key is provided in

Table 3.

1.5 Medical Device Nomenclature Description / Text

The “Classificazione Nazionale dei Dispositivi medici” (CND)/European Medical Device Nomenclature (EMDN) code and descriptor for the subject device are listed in

Table 3.

1.6 Risk Class of Device

The EU device risk classifications for the HepaSphere Microspheres are listed in

Table 3.

Table 3. Device Identification Information

| Device Name | EU Device Class | Product Number | Basic UDI-DI | Single Registration Number (SRN) | CND/EMDN Code | CND/EMDN Terms |
|--|-----------------|----------------|----------------|----------------------------------|---------------|--|
| HepaSphere Microspheres Q2 20-40 µm – 25 mg | III | V125HS | 088445048755E9 | FR-MF-000005250 | C010402020303 | EMBOLIZATION IMPLANTS AND SYSTEMS / Embolization Particles and Microspheres |
| HepaSphere Microspheres Q2 20-40 µm – 50 mg | III | V150HS | 088445048755E9 | FR-MF-000005250 | C010402020303 | EMBOLIZATION IMPLANTS AND SYSTEMS / Embolization Particles and Microspheres |
| HepaSphere Microspheres 20-40 µm – 25 mg | III | V125HS | 088445048755E9 | FR-MF-000005250 | C010402020303 | EMBOLIZATION IMPLANTS AND SYSTEMS / Embolization Particles and Microspheres |
| HepaSphere Microspheres 20-40 µm – 50 mg | III | V150HS | 088445048755E9 | FR-MF-000005250 | C010402020303 | EMBOLIZATION IMPLANTS AND SYSTEMS / Embolization Particles and Microspheres |
| HepaSphere Microspheres 30-60 µm – 25 mg | III | V225HS | 088445048755E9 | FR-MF-000005250 | C010402020303 | EMBOLIZATION IMPLANTS AND SYSTEMS / Embolization Particles and Microspheres |
| HepaSphere Microspheres | III | V250HS | 088445048755E9 | FR-MF-000005250 | C010402020303 | EMBOLIZATION IMPLANTS AND SYSTEMS / Embolization Particles and Microspheres |



| Device Name | EU Device Class | Product Number | Basic UDI-DI | Single Registration Number (SRN) | CND/EMDN Code | CND/EMDN Terms |
|---|-----------------|----------------|----------------|----------------------------------|---------------|--|
| 30-60 µm – 50 mg | | | | | | |
| HepaSphere Microspheres 50-100 µm – 25 mg | III | V325HS | 088445048755E9 | FR-MF-000005250 | C010402020303 | EMBOLIZATION IMPLANTS AND SYSTEMS / Embolization Particles and Microspheres |
| HepaSphere Microspheres 50-100 µm – 50 mg | III | V350HS | 088445048755E9 | FR-MF-000005250 | C010402020303 | EMBOLIZATION IMPLANTS AND SYSTEMS / Embolization Particles and Microspheres |
| HepaSphere Microspheres 100-150 µm – 25 mg | III | V525HS | 088445048755E9 | FR-MF-000005250 | C010402020303 | EMBOLIZATION IMPLANTS AND SYSTEMS / Embolization Particles and Microspheres |
| HepaSphere Microspheres 100-150 µm – 50 mg | III | V550HS | 088445048755E9 | FR-MF-000005250 | C010402020303 | EMBOLIZATION IMPLANTS AND SYSTEMS / Embolization Particles and Microspheres |
| HepaSphere Microspheres 150-200 µm – 25 mg | III | V725HS | 088445048755E9 | FR-MF-000005250 | C010402020303 | EMBOLIZATION IMPLANTS AND SYSTEMS / Embolization Particles and Microspheres |
| HepaSphere Microspheres 150-200 µm – 50 mg | III | V750HS | 088445048755E9 | FR-MF-000005250 | C010402020303 | EMBOLIZATION IMPLANTS AND SYSTEMS / Embolization Particles and Microspheres |

1.7 Year of EU Market Introduction

The year that the HepaSphere Microspheres was first placed on the European Union market is presented in Table 4.

1.8 Authorised Representative (if applicable)

Non applicable.

1.9 Notified Body name and NB's Single Identification Number

The Notified Body (NB) involved in the conformity assessment of the HepaSphere Microspheres in accordance with Annex IX of the Medical Device Regulation 2017/745 of the European Union and responsible for validating the SSCP is listed in Table 4.

The NB Single Identification Number is listed in Table 4.

Table 4. Legal manufacturer and Notified Body Information

| Device Name | Year Placed on EU Market | Legal Manufacturer | | Notified Body | |
|--|--------------------------|---------------------------|-----------------|---------------|-----------|
| | | Name | SRN | Name | ID Number |
| HepaSphere Microspheres Q2 20-40 µm – 25 mg | 2019 | Biosphere Medical S.A. | FR-MF-000005250 | GMED | 0459 |
| HepaSphere Microspheres Q2 20-40 µm – 50 mg | 2019 | Biosphere Medical S.A. | FR-MF-000005250 | GMED | 0459 |
| HepaSphere Microspheres 20-40 µm – 25 mg | 2019 | Biosphere Medical S.A. | FR-MF-000005250 | GMED | 0459 |
| HepaSphere Microspheres 20-40 µm – 50 mg | 2019 | Biosphere Medical S.A. | FR-MF-000005250 | GMED | 0459 |
| HepaSphere Microspheres 30-60 µm – 25 mg | 2013 | Biosphere Medical S.A. | FR-MF-000005250 | GMED | 0459 |
| HepaSphere Microspheres 30-60 µm – 50 mg | 2013 | Biosphere Medical S.A. | FR-MF-000005250 | GMED | 0459 |
| HepaSphere Microspheres 50-100 µm – 25 mg | 2006 | Biosphere Medical S.A. | FR-MF-000005250 | GMED | 0459 |
| HepaSphere Microspheres 50-100 µm – 50 mg | 2006 | Biosphere Medical S.A. | FR-MF-000005250 | GMED | 0459 |
| HepaSphere Microspheres 100-150 µm – 25 mg | 2006 | Biosphere Medical S.A. | FR-MF-000005250 | GMED | 0459 |
| HepaSphere Microspheres 100-150 µm – 50 mg | 2006 | Biosphere Medical S.A. | FR-MF-000005250 | GMED | 0459 |
| HepaSphere Microspheres 150-200 µm – 25 mg | 2006 | Biosphere Medical S.A. | FR-MF-000005250 | GMED | 0459 |
| HepaSphere Microspheres 150-200 µm – 50 mg | 2006 | Biosphere Medical S.A. | FR-MF-000005250 | GMED | 0459 |

2.0 Intended Use of the Device

2.1 Intended Purpose

HepaSphere Microspheres are designed for controlled, targeted embolization.

2.2 Indications

HepaSphere Microspheres are indicated for use in embolization of blood vessels with or without delivery of doxorubicin HCl for therapeutic or



preoperative purposes in the following procedures:

- Embolization of hepatocellular carcinoma
- Embolization of metastases to the liver.

HepaSphere Microspheres loaded with irinotecan are indicated for use in:

- Embolization of metastatic colorectal cancer (mCRC) to the liver.

2.3 Intended Patient Groups

The device HepaSphere Microspheres is intended for therapeutic or preoperative embolization for:

- Patients with hepatocellular carcinoma
- Patients with metastases to the liver
- Patients with metastatic colorectal cancer (mCRC) to the liver

Transarterial chemoembolization is indicated for patients with intermediate HCC (BCLC B disease) that are not suitable for ablation intervention in Child-Pugh A or B cirrhotic with performance status 0–1. Approximately 90% of HCCs are associated with a known underlying etiology, most frequently chronic viral hepatitis (B and C). The gender ratio is 70% of men for 30% of women with a mean age of 64 years old.

Metastases to the liver, including mCRC correspond to an advanced stage of primary tumors. The gender ratio is 70% of men for 30% of women with a mean age of 61 years old.

2.4 Contraindications:

All indications

- Patients intolerant to vascular occlusion procedures
- Vascular anatomy or blood flow precluding correct catheter placement or embolic injection
- Presence or suspicion of vasospasm
- Presence or likely onset of haemorrhage



- Presence of severe atheromatous disease
- Presence of collateral vessel pathways potentially endangering normal territories during embolization
- High flow arteriovenous shunts or fistulae with luminal diameter greater than the selected size of HepaSphere Microspheres
- Vascular resistance peripheral to the feeding arteries precluding passage of HepaSphere Microspheres into the lesion
- Do not use in pulmonary vasculature, coronary and central nervous system vasculature
- Known sensitivity to poly vinyl alcohol-co-sodium acrylate

3.0 Device Description

HepaSphere Microspheres are part of a family of embolic agents based on Merit Medical's proprietary technology. These spheres are designed for controlled, targeted embolisation.

HepaSphere Microspheres are made of an acrylic copolymer. They are biocompatible, hydrophilic, non-resorbable, expandable and conformable microspheres. HepaSphere Microspheres swell upon exposure to aqueous solutions. They can be loaded with doxorubicin HCl or irinotecan and are able to release the drug locally at the embolization site.

The microspheres are contained in a sterile, 10 ml vial, with a crimped cap, individually packaged in a sealed pouch. Contents: 25 mg or 50 mg of dry HepaSphere Microspheres per vial to be reconstituted before use. One (1) sealed unit packed is placed inside a carton box with one (1) IFU.

3.1 Materials/Substances in Contact with Patient Tissues and Operating principles

Only the acrylic copolymer (poly vinyl alcohol-co-sodium acrylate) microspheres (Figure 1) will be in contact with vessels of the patient.

The procedure of arterial embolization is similar for all arteries. Appropriately sized microspheres for target vessel occlusion are chosen by the trained interventional radiologist. The delivery procedure involves arterial access through an artery, using a guidewire and microcatheter under fluoroscopic guidance. Once the catheter tip is placed in the artery(ies) supplying the targeted tissue, HepaSphere Microspheres mixed with a non-ionic contrast agent are delivered in a controlled manner under visualization and mechanically occlude the feeding vessel(s) to interrupt artery blood flow to the targeted area.

HepaSphere Microspheres have properties of loading with chemotherapeutic agents. The loading of HepaSphere Microspheres with chemotherapeutic agents occurs by 2 mechanisms:

- passive absorption by swelling from its dry state in an aqueous solution of the drug
- ionic bonding between negatively charged carboxylate groups of HepaSphere Microspheres and positively charged amine groups such as Irinotecan.

HepaSphere Microspheres can occlude blood flow to the target tissue and deliver a local and sustained dose of chemotherapeutic agent directly to the tumor. HepaSphere Microspheres enables high drug concentration that is targeted and delivered directly to the tumor site, resulting in fewer drug-related adverse events.




Figure 1. Picture of HepaSphere Microspheres

3.2 Previous Generations or Variants

There are no applicable prior device generations or variants.

3.3 Accessories, Devices and Product to be Used in Combination with HepaSphere Microspheres

HepaSphere Microspheres are compatible with the microcatheters listed in Table 5.

**Table 5. HepaSpheres Microspheres Catheter Compatibility**

| Dry Size Range (µm) | Size after reconstitution (µm) | Color Code | 25 mg | 50 mg | Minimum Catheter ID |
|---------------------|--------------------------------|------------|--------|--------|---------------------|
| 20-40 | 80-160 | Grey | V125HS | V150HS | 0.020 in (0.51 mm) |
| 30-60 | 120-240 | Orange | V225HS | V250HS | 0.021 in (0.53 mm) |
| 50-100 | 200-400 | Yellow | V325HS | V350HS | 0.021 in (0.53 mm) |
| 100-150 | 400-600 | Blue | V525HS | V550HS | 0.024 in (0.61 mm) |
| 150-200 | 600-800 | Red | V725HS | V750HS | 0.027 in (0.63 mm) |

Abbreviations: ID = inner diameter, in = inch, mg = milligram, mm = millimeter, µm = micrometer

Table 6 summarizes the accessories not supplied with the product but required for its use as defined in product IFU.

Table 6. Accessories not included with the device but necessary for use

| Procedure | | Component | Comment |
|------------------------------|----------------------|---|--|
| Preparation for embolization | Without drug (bland) | Saline solution | Reconstitution medium: The microspheres are prepared with a mixture of 50% saline solution and 50% non-ionic contrast agent (for visualization under fluoroscopy). |
| | | Contrast medium | |
| | | 10-mL syringe and 20-gauge diameter or larger needle | To inject the reconstitution medium into the HepaSpheres vial. |
| | | 30-mL syringe and 20-gauge or larger needle | Aspirate the contents of the vial into a 30-mL syringe. |
| | With doxorubicin | Up to 75mg doxorubicin 20-mL saline solution when doxorubicin in powder 2 x 30-mL syringe 1 x 20-gauge diameter or larger needle | To prepare the microspheres with doxorubicin. |



| Procedure | | Component | Comment |
|-----------------------|--------------------|--|--|
| Delivery instructions | With irinotecan | 100mg irinotecan 1 x syringe and 20-gauge or larger needle | To prepare the microspheres with irinotecan. |
| | | Injection syringe no larger than 3-mL (1-mL injection syringe recommended) | The microspheres are transferred into an injection syringe through a three-way stopcock. |
| | Three-way stopcock | | |
| | | Microcatheter | The microspheres are injected into the patient through a microcatheter. |

Abbreviations: mg = milligram, mL = milliliter

4.0 Risks and Warnings

4.1 Residual Risks and Undesirable Effects

The potential complications/undesirable side effects related to the HepaSphere Microspheres device as identified in the Instructions For Use are summarized in Table 7.

Table 7. HepaSphere Microspheres: Potential Complications

| Product Configuration | Potential Adverse Events |
|---|---|
| HepaSphere Microspheres HepaSphere Q2 Microspheres | <p>Vascular embolization is a high-risk procedure. Complications may occur at any time during or after the procedure, and may include, but are not limited to, the following:</p> <ul style="list-style-type: none"> • Post-embolization syndrome (such as nausea, vomiting, pain, fever) • Fatigue and loss of appetite • Hypertension • Liver disorders or failure (including liver enzyme anomalies and ascites) • Complications related to catheterization (e.g., haematoma at the site of entry, clot formation at the tip of the catheter and subsequent dislodgement, and nerve and/or circulatory injuries which may result in leg injury) • Vessel or lesion rupture and hemorrhage • Vasospasm |



| Product Configuration | Potential Adverse Events |
|-----------------------|---|
| | <ul style="list-style-type: none"> • Recanalisation • Allergic reaction to medications (e.g., analgesics) • Allergic reaction to non-ionic contrast media or embolic material • Undesirable reflux or passage of HepaSpheres Microspheres into normal arteries adjacent to the targeted lesion or through the lesion into other arteries or arterial beds, such as the internal carotid artery, pulmonary, or coronary circulation • Pulmonary embolism due to arteriovenous shunting • Pleural effusion • Ischemia at an undesired location, including ischemic stroke, ischemic infarction (including myocardial infarction), and tissue necrosis • Capillary bed occlusion and tissue damage (cholecystitis, cholangitis, pancreatitis) • Paralysis resulting from untargeted embolization or ischemic injury from adjacent tissue oedema • Blindness, hearing loss, and loss of smell • Foreign body reactions necessitating medical intervention • Infection necessitating medical intervention (including liver abscess) • Death |

4.2 Warnings and Precautions

Table 8. HepaSpheres Microspheres: Warning and Precautions

| Product Configuration | Labeling |
|---|--|
| HepaSpheres Microspheres HepaSpheres Q2 Microspheres | <p>Warnings</p> <ul style="list-style-type: none"> • HepaSpheres Microspheres size must be chosen after consideration of the arteriovenous angiographic appearance. HepaSpheres Microspheres size should be selected both to be appropriate for the size of the vessel feeding the target and to prevent passage from artery to vein. • Some of the HepaSpheres Microspheres may be slightly outside of the range, so the physician should be sure to carefully select the size of HepaSpheres Microspheres according to the size of the target vessels at the desired level of occlusion in the vasculature and after consideration of the arteriovenous angiographic appearance. • Because of the significant complications of untargeted embolization, extreme caution should be used for any procedures involving the extracranial circulation encompassing the head and neck, and the physician should carefully weigh the potential benefits of using embolization against the risks and potential complications of the procedure. These complications can include blindness, hearing loss, loss of smell, paralysis, and death. |



| Product Configuration | Labeling |
|-----------------------|--|
| | <ul style="list-style-type: none"> • Serious radiation induced skin injury may occur to the patient due to long periods of fluoroscopic exposure, large patient, angled x-ray projections and multiple image recording runs or radiographs. Refer to your facility's clinical protocol to ensure the proper radiation dose is applied for each specific type of procedure performed. • Onset of radiation injury to the patient may be delayed. Patients should be counselled on potential radiation effects, what to look for and whom to contact if symptoms occur. • HepaSphere Microspheres MUST NOT be reconstituted in sterile water for injection. Reconstitution in sterile water results in extensive swelling that renders the injection of HepaSphere Microspheres very difficult or may prevent injection. • Do not reconstitute HepaSphere Microspheres with Lipiodol / Ethiodol. • Pay careful attention for signs of untargeted embolization. During injection carefully monitor patient vital signs to include SaO2 (e.g., hypoxia, CNS changes). Consider terminating the procedure, investigating for possible shunting, or increasing Microspheres size if any signs of untargeted embolization occur or patient symptoms develop. • Consider upsizing the Microspheres if angiographic evidence of embolization does not quickly appear evident during injection of the Microspheres. <p><u>Warnings about use of small microspheres:</u></p> <ul style="list-style-type: none"> • Careful consideration should be given whenever use is contemplated of embolic agents that are smaller in diameter than the resolution capability of your imaging equipment. The presence of arteriovenous anastomoses, branch vessels leading away from the target area or emergent vessels not evident prior to embolization can lead to untargeted embolization and severe complications. • Microspheres smaller than 100 microns are more likely to terminate circulation to distal tissue. Greater potential of ischemic injury results from use of smaller sized microspheres and consideration must be given to the consequence of this injury prior to embolization. The potential consequences include swelling, necrosis, paralysis, abscess and/or stronger post-embolization syndrome. • Post embolization swelling may result in ischemia to tissue adjacent to target area. Care must be given to avoid ischemia of intolerant, non-targeted tissue such as nervous tissue. <p>Precautions</p> <ul style="list-style-type: none"> • HepaSphere Microspheres must only be used by physicians trained in vascular embolization procedures. The size and quantity of microspheres must be carefully selected according to the lesion to be treated and the potential presence of shunts. Only the physician can decide the most appropriate time to stop the injection of HepaSphere Microspheres. |



| Product Configuration | Labeling |
|-----------------------|--|
| | <ul style="list-style-type: none"> • Do not use if the vial, cap, or pouch appear damaged. • For single patient use only - Contents supplied sterile - Never reuse, reprocess, or resterilize the contents of a vial that has been opened. Reusing, reprocessing or resterilizing may compromise the structural integrity of the device and or lead to device failure, which in turn may result in patient injury, illness or death. Reusing, reprocessing or resterilizing may also create a risk of contamination of the device and or cause patient infection or cross infection including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device may lead to injury, illness or death of the patient. All procedures must be performed according to accepted aseptic technique. • HepaSphere Microspheres MUST NOT be used in their original dry state. They must be reconstituted before use. • HepaSphere Microspheres swell in aqueous solution. The magnitude of swelling depends on the ionic concentration of the solution. Refer to section "SWELLING BEHAVIOR" of the product's Instructions For Use (IFU). • HepaSphere Microspheres are compressible and can be injected easily through microcatheters. However, injection of the HepaSphere Microspheres before they are fully expanded could result in failure to reach the intended embolization target and possible embolization of a larger tissue area. • Note: Maximum recommended concentration of doxorubicin HCl is 5mg/ ml. Concentrations of doxorubicin HCl above 5mg/ml substantially increase the solution viscosity and make it difficult to handle with HepaSphere Microspheres. Maximum recommended concentration of irinotecan is 20 mg/ml. • Patients with known allergies to non-ionic contrast media may require corticosteroids prior to embolization. Additional evaluations or precautions may be necessary in managing periprocedural care for patients with the following conditions: <ul style="list-style-type: none"> ○ Bleeding diathesis or hypercoagulative state ○ Immunocompromise • Note: If loading HepaSphere Microspheres with doxorubicin HCl or irinotecan, refer to the appropriate drug IFU for information concerning contraindications, warnings, precautions, potential complications, dosage, and patient management before use. |

4.3 Other Relevant Safety Aspects

There have been no field corrective actions or recalls for HepaSphere Microspheres.



5.0 Summary of Clinical Evaluation and Postmarket Clinical Follow-up

5.1 Summary of Clinical Data for the Equivalent Device

Not applicable.

5.2 Summary of Clinical Investigations of the Subject Device

mCRC Registry

A post market clinical study has been implemented to provide further demonstration of the safety and effectiveness of HepaSphere Microspheres for delivery of irinotecan in clinical use for treating metastatic colorectal cancer. This registry consists in the prospective collection of clinical use data for HepaSphere Microspheres with delivery of irinotecan for the treatment of patients with metastatic colorectal cancer. A total of 105 patients have been enrolled and treated. The protocol for this study (CRC-P4-16-01 V1.0): Prospective Registry of Transarterial Chemoembolization of Metastatic Colorectal Cancer to the Liver with HepaSphere™ Microspheres loaded with irinotecan was sent to LNE-G-Med on May 10, 2016 and was approved by the Ethic Committee end of May 2016.

5.3 Summary of Clinical Data from Other Sources

A comprehensive literature review was performed to gather clinical data in support of continued CE-marking and to assist in documenting conformity with the relevant European MDR concerning device safety and performance. Literature search strategies were designed to identify articles relevant to the HepaSphere Microspheres. The results of the literature review also provide verification that all clinical hazards have been addressed in the subject device risk analysis. Both favourable and unfavourable references have been identified and summarized.

5.4 Overall Summary of Clinical Performance and Safety

The devices HepaSphere Microspheres have been used safely and effectively for:

- Embolisation of hepatocellular carcinoma
- Embolisation of metastases to the liver
- Embolisation of metastatic colorectal cancer (mCRC) to the liver

Clinical Benefits/Performance Analysis



Performance data from the HepaSpheres Microspheres (HS) clinical literature data and State-Of-the-Art and Safety and Performance literature of Similar devices (SD) are summarized in Table 9 and Table 10.

Similar medical devices identified in the state-of-the-art literature used for embolotherapy, and quite like HepaSpheres Microspheres are:

- DC Bead™ in EU / LC Bead™ in US (Boston Scientific)
- Lifepearl® drug elutable microspheres in EU / HydroPearl® in US (Terumo interventional systems)
- Embozene TANDEM™ Microspheres in EU / Oncozene™ Microspheres in US (Celonova/Boston scientific)

Table 9. Comparative Performance of TACE procedure in HCC and liver metastases

| Device Type/Application | HepaSpheres Microspheres N=1176 | Similar Devices N=1387 | P-value p1-p2 ≠ 0 |
|---|------------------------------------|---------------------------|----------------------|
| Average technical success rate | 98% (1152/1176) | 99% (1373/1387) | P > 0.05 |
| Average complete tumour response rate (at 3 months) | 35% (412/1176) | 30% (416/1387) | P = 0.007 |
| Average objective tumor response rate (at 3months) | 67% (788/1176) | 64% (888/1387) | P > 0.05 |
| Median progression free survival (months) | 12 [Range: 8-24] | 14 [Range: 2-24] | N/A |
| Median overall survival | 27 [Range: 14-37] | 25 [Range: 14-44] | N/A |

Abbreviations: CI = confidence interval.

‡ Statistically significant (P<0.05)

Table 10. Comparative Performance for TACE procedure of mCRC to the Liver

| Device Type/Application | HepaSpheres Microspheres N=76 | Similar Devices N=767 | P-value p1-p2 ≠ 0 |
|---|----------------------------------|--------------------------|----------------------|
| Average technical success rate | 100% (76/76) | 100% (767/767) | P > 0.05 |
| Average complete tumour response rate (at 3 months) | 15% (11/76) | 15% (115/767) | P = 1.0 |
| Average objective tumor response rate (at 3months) | 55% (42/76) | 56% (429/767) | P = 0.9 |
| Median progression free survival (months) | 5 [Range: 3-10] | 8 [Range: 4-11] | N/A |
| Median overall survival | 23 [Range: 8-38] | 20 [Range: 7-25] | N/A |

Abbreviations: CI = confidence interval.

‡ Statistically significant (P<0.05)



Embolization with HepaSphere Microspheres is a minimally invasive treatment that is effective for:

- Delaying disease progression and improving survival in patients with hepatocellular carcinoma and metastases to the liver
- Delaying disease progression and improving survival in patients with metastatic colorectal cancer to the liver.

The clinical benefits for the subject devices have been substantiated via objective evidence from the clinical data from literature. The ability of the subject devices to achieve the intended performances was assessed and documented. The results of the performance analysis demonstrate that the subject devices perform as intended and are State-Of-the-Art.

The published studies related to the use of HepaSphere Microspheres in HCC and liver metastases are summarized in Table 11. The published studies related to the use of HepaSphere Microspheres in mCRC to the liver are summarized in Table 12.

Table 11. HepaSphere Microspheres: Literature Summary for HCC and Liver Metastases

| Author (Year) Study Design | Indication | n | Device | Drug | Follow-up (months) | Technical Success Rate | CR | ORR | DCR | PFS (months) | Median OS (months) |
|-------------------------------------|------------------|-----|--------|---------------------------------------|-----------------------|---------------------------|-----|-----|------|-----------------|-----------------------|
| Gross (2008) Observational study | HCC | 18 | HS | Doxorubicin Epirubicin | 6 | 100% | 52% | 77% | 100% | ND | ND |
| Osuga (2008) Retrospective | HCC | 59 | HS | Bland | 31 | 99% | 22% | 64% | 96% | ND | 30 |
| Jarzabek (2011) Prospective | Liver Metastases | 15 | HS | Doxorubicin | 2 | 93% | ND | 27% | 60% | ND | ND |
| Van Malenstine (2011) RCT | HCC | 16 | HS | Doxorubicin | 2 | ND | ND | ND | 77% | ND | ND |
| Haug (2012) Case Report | HCC | 1 | QS+ | Doxorubicin Cisplatin Mitomycin | NA | NA | NA | NA | NA | NA | NA |
| Idilman (2012) Retrospective | HCC | 24 | HS | Doxorubicin | 19 | 100% | 13% | 25% | 79% | ND | 14 |
| Dekervel (2013) Prospective | HCC | 64 | HS | Doxorubicin | 14 | 100% | ND | 45% | 75% | ND | 21 |
| Dorn (2013) Retrospective | HCC | 190 | QS+ | Doxorubicin | 48 | 100% | 43% | 79% | 100% | ND | 22 |



| Author (Year) Study Design | Indication | n | Device | Drug | Follow-up (months) | Technical Success Rate | CR | ORR | DCR | PFS (months) | Median OS (months) |
|--------------------------------------|-----------------------------|----|--------|---------------------------|-----------------------|---------------------------|-----|------|------|-----------------|-----------------------|
| Malagari (2013) Prospective | HCC | 45 | HS | Doxorubicin | 16 | 100% | 18% | 69% | 89% | ND | 16 |
| Moschouris (2013) Retrospective | HCC | 47 | HS | Doxorubicin | 15 | ND | 11% | 57% | 91% | 24 | 33 |
| Bishay (2014) Retrospective | HCC | 20 | QS+ | Doxorubicin | 10 | 100% | 30% | 65% | 95% | ND | ND |
| Hetta (2014) Prospective | HCC | 50 | HS | Doxorubicin | 6 | 100% | 42% | 80% | 96% | ND | ND |
| Klass (2014) Prospective | HCC | 24 | HS | Doxorubicin | 1 | 96% | 61% | 65% | 100% | ND | ND |
| Amer (2015) Prospective | HCC | 52 | HS | Doxorubicin | 12 | 100% | 77% | 100% | 100% | ND | ND |
| Dansey (2015) Case Report | HCC | 1 | QS+ | Doxorubicin | NA | NA | NA | NA | NA | NA | NA |
| Duan (2015) Retrospective | HCC | 26 | QS+ | Doxorubicin | 3 | 100% | 19% | 54% | 69% | ND | ND |
| Ginsburg (2015) Retrospective | HCC | 89 | QS+ | Doxorubicin Epirubicin | 56 | 100% | 88% | 94% | 99% | 9 | 39 |
| Hiraki (2015) Prospective | HVT (various, incl. HCC) | 24 | HS | Bland | 3 | 100% | ND | ND | ND | ND | ND |
| Kucukay (2015) Retrospective | HCC | 53 | HS | Doxorubicin | 80 | 97% | ND | ND | ND | 11 | 37 |
| Malagari (2015) Systematic review | HCC | NA | HS | NA | NA | NA | NA | NA | NA | NA | NA |
| Vasnani (2016) Retrospective | HCC | 42 | QS+ | Doxorubicin Epirubicin | ND | ND | 86% | 95% | 95% | ND | ND |
| Bonne (2017) Retrospective | Liver Metastases | 17 | HS/QS+ | Doxorubicin | 3 | 100% | 0% | 82% | 82% | ND | ND |
| Cavalcante (2017) Prospective | HCC | 17 | HS | Doxorubicin | 2 | 100% | 29% | 65% | 94% | ND | ND |



| Author (Year) Study Design | Indication | n | Device | Drug | Follow-up (months) | Technical Success Rate | CR | ORR | DCR | PFS (months) | Median OS (months) |
|-----------------------------------|-----------------------------|-----|--------|-------------|-----------------------|---------------------------|-----|-----|-----|-----------------|-----------------------|
| Sun (2017) Prospective | HCC and liver metastases | 30 | HS | Doxorubicin | 1 | 100% | 7% | 63% | 87% | ND | ND |
| Zurstrassen (2017) Prospective | HCC | 18 | HS | Doxorubicin | 6 | 83% | 40% | 53% | 93% | ND | 31 |
| Malagari (2019) Prospective | HCC | 142 | HS | Doxorubicin | 47 | ND | 36% | 83% | 96% | 9 | 31 |
| Chen (2020) Retrospective | HCC | 51 | HS | Doxorubicin | 6 | 100% | 14% | 78% | 94% | ND | ND |
| Chiu (2020) Retrospective | HCC | 42 | HS | Doxorubicin | 12 | ND | 19% | 60% | 81% | 8 | 24 |

Abbreviations: CR = complete response, DCR = disease control rate, HS = HepaSphere, ORR = objective response rate, OS = overall survival, PFS = progression-free survival, QS = Quadrasphere
 †Quadrasphere (QS) is the microsphere configuration available only in the US

Table 12. HepaSphere Microspheres Loaded with Irinotecan: Literature Summary for mCRC to the Liver

| Author (Year) Study Design | Indication | n | Device | Drug | Follow-up (months) | Technical Success rate | CR | ORR | DCR | PFS (months) | Median OS (months) |
|-------------------------------|------------|----|--------|------------|-----------------------|---------------------------|-----|-----|-----|-----------------|-----------------------|
| Huppert (2013) Prospective | mCRC | 29 | HS | Irinotecan | 15 | 100% | 24% | 72% | 86% | 5 | 8 |
| Mansour (2016) Prospective | mCRC | 22 | HS | Irinotecan | 39 | 100% | 0% | 59% | 82% | ND | ND |
| Ranieri (2016) Prospective | mCRC | 25 | HS | Irinotecan | 42 | 100% | 22% | 35% | 87% | ND | 37 |

Abbreviations: CR = complete response, DCR = disease control rate, ORR = objective response rate, OS = overall survival, PFS = progression-free survival

Clinical Risks/Safety Analysis

Safety data for the HepaSpheres Microspheres have been analysed through a review of the peer-reviewed literature and post market data. As illustrated by the data from Table 13 and Table 14 **Erreur ! Source du renvoi introuvable.**, HepaSpheres Microspheres exhibit very low major and minor adverse event rates, and these rates compare favourably with those reported for other embolics in the clinical literature data and SOA literature. No new safety concerns specific to the subject device were identified in this evaluation, and the rates reported in the literature are consistent with available data for State-Of-the-Art similar devices (SD).

Table 13. Comparative Safety for HCC and liver metastases

| Adverse Events in HCC From Literature search* | HS rate (N= 1176) | SD rate (N= 1387) | P -value | SOA Threshold |
|--|--------------------------|--------------------------|------------------|----------------------|
| PES related events (Fever, Pain, Nausea, Vomiting) | 38% | 24% | <i>P</i> < 0.001 | ≤ 60% |
| Fatigue, loss of appetite | 2% | 2% | <i>P</i> > 0.05 | ≤ 54% |
| Liver enzyme abnormalities | 2% | 1% | <i>P</i> > 0.05 | ≤ 60% |
| Infection (including liver abscess, septicemia) | 1% | 1% | <i>P</i> > 0.05 | ≤ 3% |
| Acute ascites | 0.6% | 1% | <i>P</i> > 0.05 | ≤ 8% |
| Undesired ischemia | 1% | 0.1% | <i>P</i> = 0.01 | ≤ 5% |
| Acute cholecystitis, cholangitis | 0.2% | 1% | <i>P</i> > 0.05 | ≤ 13% |
| Acute pancreatitis | 0.2% | 0.2% | <i>P</i> > 0.05 | - |
| Pulmonary embolism | 0.2% | 0% | <i>P</i> > 0.05 | - |
| Pleural effusion | 0.2% | 0.2% | <i>P</i> > 0.05 | ≤ 6% |
| 30-day mortality | 0.2% | 1% | <i>P</i> > 0.05 | - |
| Allergic reaction to contrast | 0.1% | 1% | <i>P</i> = 0.003 | - |
| Catheterization related complications (hematoma) | 0.1% | 0.1% | <i>P</i> > 0.05 | ≤ 6 % |
| Cardiac disorders | 0.1% | 0% | <i>P</i> > 0.05 | - |
| Splenic infarction | 0.1% | 0% | <i>P</i> > 0.05 | - |
| Hypertension | 0% | 2% | <i>P</i> < 0.001 | - |
| Liver failure | 0% | 1% | <i>P</i> = 0.02 | ≤ 1.4% |
| Acute renal failure | 0% | 0% | <i>P</i> > 0.05 | - |

Statistically significant (*P*<0.05)

*Mean Follow-up: 16 months for HS; 16 months for SD



Table 14. Comparative Safety for mCRC to the liver

| Adverse Events in mCRC From Literature search | HS rate (N= 76) | SD rate (N= 767) | P -value | SOA Threshold |
|--|-----------------|------------------|------------------|---------------|
| PES related events | 48% | 35% | <i>P</i> = 0.02 | ≤ 60% |
| Fatigue, loss of appetite | 20% | 5% | <i>P</i> < 0.001 | ≤ 54% |
| Acute ascites | 4% | 0.1% | <i>P</i> = 0.003 | ≤ 8% |
| Infection (including liver abscess, septicemia) | 1% | 2% | <i>P</i> > 0.05 | ≤ 3% |
| Cardiac Disorder | 0% | 0% | <i>P</i> > 0.05 | - |
| Splenic infarction | 0% | 0% | <i>P</i> > 0.05 | - |
| Hypertension | 0% | 3% | <i>P</i> > 0.05 | - |
| Catheterization related complications (hematoma) | 0% | 0% | <i>P</i> > 0.05 | ≤ 6% |
| Liver enzyme abnormalities | 0% | 13% | <i>P</i> < 0.001 | ≤ 60% |
| Liver failure | 0% | 1% | <i>P</i> > 0.05 | ≤ 1.4% |
| Acute renal failure | 0% | 0% | <i>P</i> > 0.05 | - |
| Acute cholecystitis, cholangitis | 0% | 1.2% | <i>P</i> > 0.05 | ≤ 13% |
| Acute pancreatitis | 0% | 0.4% | <i>P</i> > 0.05 | - |
| Allergic reaction to contrast | 0% | 0% | <i>P</i> > 0.05 | - |
| pleural effusion | 0% | 0% | <i>P</i> > 0.05 | ≤ 6% |
| Pulmonary embolism | 0% | 0.1% | <i>P</i> > 0.05 | - |
| Undesired ischemia | 0% | 0% | <i>P</i> > 0.05 | ≤ 5% |
| 30-day mortality | 0% | 0.1% | <i>P</i> > 0.05 | - |

Statistically significant (*P*<0.05)

*Mean Follow-up: 32 months HS; 18 months SD

As illustrated by the above data, the HepaSpheres Microspheres exhibit low major and minor adverse event rates, which compare favourably with those reported for comparable embolization devices and alternative therapies in the clinical literature data and SOA literature.

The HepaSpheres Microspheres were deemed consistent with the benchmark devices for safety and performance in this patient population. The devices in the HepaSpheres Microspheres are well established, having demonstrated acceptable safety and performance profile since first commercialization in 2006. Based on design verification/validation testing results, safety and performance outcomes in the literature, and PMS



data, there are no known uncertainties regarding safety and performance of the subject device or the intended use. The known risks are well-documented, and the risk of occurrence is low and not associated with any safety or performance signals.

When used in accordance with the IFUs, the risks associated with the use of HepaSphere Microspheres are low and outweighed by the clinical benefits associated with use. The clinical evidence demonstrate that the HepaSphere Microspheres meet the established safety and performance acceptance criteria, with a benefit-risk profile aligned with the current state-of-the-art.

5.5 Postmarket Clinical Follow-up

Clinical Evaluation Report of HepaSphere Microspheres has concluded that for the indications stated in the IFU, the evidence presented is adequate to support the long-term safety and performance of subject device.

The postmarket clinical follow-up of HepaSphere Microspheres includes the following activities:

- Screening of scientific literature
- Post Market Clinical Follow Up Study (prospective registry)

A Post Market Clinical Follow-up study is ongoing to gather more data on the safety and effectiveness of HepaSphere Microspheres for the indication transarterial chemoembolization of metastatic colorectal cancer (mCRC) to the liver, which is a more recent indication (CE-mark: 2015).

Proactive PMCF data will be collected and assessed on 105 patients among 2 sites (France and Greece). Analysis will be performed when all subjects enrolled have been followed for survival for two years, are considered lost to follow up, or have died, whichever comes first.

Effectiveness of mCRC embolization will be evaluated by the median overall survival of subjects (primary objective), objective response rate, best tumor response, median liver progression-free survival and time to progression (secondary objectives).



6.0 Therapeutic Alternatives

The therapeutic alternatives for each indication are summarized in Table 15.

Table 15. Summary of treatment options for the target population

| Treatment options of HCC and metastases to the liver including mCRC | | Reference |
|---|--|---|
| Available treatments | <p>Treatment options and Interventions for the patients with intermediate liver tumors are the following:</p> <ul style="list-style-type: none"> • Transarterial chemoembolisation (TACE) is the most widely used primary treatment for unresectable liver tumors, and it is the recommended first-line therapy for patients with intermediate-stage disease. <ul style="list-style-type: none"> ○ Drug eluting microspheres Transarterial chemoembolisation (DEM-TACE) ○ Conventional Transarterial chemoembolisation (cTACE) is the most widely used primary treatment for unresectable liver tumors, and it is the recommended first-line therapy for patients with intermediate-stage disease. • Selective internal radiation therapy (SIRT) also called Transarterial radioembolization (TARE) | EASL 2018 |
| Drug eluting microspheres Transarterial chemoembolisation (DEM-TACE) | | |
| Description | DEM TACE is a strategy allowing maximum and sustained intratumoral concentration of the chemotherapeutic agent with minimal systemic exposure, along with calibrated tumour vessel obstruction. Embolic microspheres have the ability to sequester chemotherapeutic agents and release them in a controlled mode over a one-week period. | EASL 2018 |
| Summary of clinical benefit | Comparative data are limited to irinotecan-based drug-eluting beads in a small phase II cohort in previously treated patients showing a benefit versus systemic chemotherapy. | Van Custem 2016 |
| Summary of clinical risk/Limits | <ul style="list-style-type: none"> • Refer to Figure 2. | Lencioni 2016 |
| Transarterial radioembolization (TARE) | | |
| Description | TARE involves the injection of implantable radioactive microspheres into tumor-feeding arteries in order to expose the tumor to highly concentrated radiation while protecting the normal parenchyma. ⁹⁰ Y is the most commonly used radioisotope and emits high-energy and pure β-rays with a half-life of 64.2 hours. The microspheres available for ⁹⁰ Y infusion are 20 to 60 μm in diameter and are made of resin or glass. | KJR 2018 |
| Summary of clinical benefit/advantages | <ul style="list-style-type: none"> • For patients with liver-limited metastases failing the available chemotherapeutic options, radioembolisation with yttrium-90 resin microspheres has been shown to prolong the time to tumour progression in the liver, | Hendlishz 2010 |
| Summary of clinical risk/limits | <ul style="list-style-type: none"> • Specific risks related to radiation which is carcinogenic itself. (Marrero et al.2018) • Biliary stricture (4%) • Gastric Ulcer (3%) • Hypervolemia (1%) • Oesophageal varices (1%) | Marrero et al. 2018 (ASSLD guideline) Sapir 2017 |

| AE Name | No. of Studies | Total No. of Patients | No. of Patients With AE | AE Rate Estimate | Lower 95% CI | Upper 95% CI |
|--|----------------|-----------------------|-------------------------|------------------|--------------|--------------|
| Fever | 91 | 7,028 | 3,700 | 57.8 | 50.2 | 65.4 |
| Liver enzyme abnormalities | 48 | 9,021 | 3,892 | 52.0 | 43.9 | 60.1 |
| PES | 40 | 3,346 | 1,032 | 47.7 | 35.4 | 60.0 |
| Abdominal pain | 69 | 5,309 | 1,781 | 42.5 | 36.0 | 48.9 |
| Fatigue/malaise | 17 | 1,633 | 457 | 39.9 | 25.8 | 54.1 |
| Anorexia/loss of appetite | 16 | 1,867 | 691 | 38.0 | 28.5 | 47.6 |
| Vomiting | 49 | 4,754 | 1,297 | 34.2 | 26.9 | 41.4 |
| Nausea | 25 | 1,218 | 361 | 32.4 | 23.0 | 41.7 |
| Hematological/bone marrow toxicity | 48 | 11,962 | 2,907 | 28.6 | 25.0 | 32.1 |
| Bilirubin-related abnormalities | 36 | 5,155 | 985 | 23.5 | 19.7 | 27.3 |
| Hepatic decompensation/deterioration of hepatic function | 23 | 3,287 | 533 | 21.8 | 14.3 | 29.2 |
| Elevated renal enzymes/renal dysfunction | 23 | 2,446 | 434 | 15.1 | 10.4 | 19.9 |
| Alopecia | 11 | 805 | 113 | 12.9 | 6.8 | 19.1 |
| Diarrhea | 14 | 1,167 | 113 | 9.0 | 5.4 | 12.7 |
| Cholecystitis | 18 | 1,549 | 47 | 8.4 | 4.1 | 12.8 |
| Skin ulcer/rash/erythema | 12 | 1,390 | 144 | 8.2 | 5.1 | 11.3 |
| Hepatic arterial complications | 20 | 3,061 | 271 | 7.2 | 5.0 | 9.5 |
| Ascites | 22 | 1,805 | 113 | 6.1 | 4.0 | 8.1 |
| Pleural effusion | 12 | 2,056 | 94 | 4.2 | 2.2 | 6.2 |
| Procedural complications | 30 | 4,145 | 212 | 4.2 | 2.6 | 5.7 |
| Hepatic encephalopathy/coma | 14 | 1,346 | 44 | 2.0 | 0.9 | 3.2 |
| Gastrointestinal bleeding (varices or ulcer) | 44 | 5,721 | 142 | 1.9 | 1.3 | 2.4 |
| Hepatic failure | 31 | 5,837 | 95 | 1.0 | 0.6 | 1.4 |
| Bacteremia/septicemia | 17 | 2,301 | 37 | 1.0 | 0.5 | 1.4 |
| Abscess | 30 | 5,138 | 67 | 0.9 | 0.6 | 1.2 |
| Renal failure | 15 | 1,488 | 22 | 0.6 | 0.2 | 1.0 |

Figure 2. Estimated Rate of Individual AEs as Assessed in the Safety Analysis (Source: Lencioni 2016)



Table 16. Summary of other treatment options

| Intervention | Specification | Reference |
|-----------------------------|--|---------------------------------------|
| Surgical resection | | |
| Description | Surgical resection of the tumours by laparoscopy or open surgery | Marrero et al. 2018 (ASSLD guideline) |
| Summary of clinical benefit | <ul style="list-style-type: none"> For patients with single tumours, well-preserved organ function, and no evidence of portal hypertension. Surgical resection offers a low perioperative mortality and is associated with survival rates of nearly 70% at 5 years. There is technically no size cut-off for tumour diameter, and large tumours can be safely resected if there is sufficient functional remnant tissue. | Marrero et al. 2018 (ASSLD guideline) |
| Summary of clinical risk | <ul style="list-style-type: none"> The risk of recurrence following resection is up to 70% at 5 years, with the most important predictors being tumour differentiation, micro- and macrovascular invasion, and the presence of satellite nodules. | Marrero et al. 2018 (ASSLD guideline) |
| Target population | Surgical resection is the treatment of choice for resectable HVT and HCC occurring in patients without cirrhosis, which accounts for 5%-10% of HCC in Western countries. | Marrero et al. 2018 (ASSLD guideline) |
| Transplantation | | |
| Description | Transplantation of the target organ (e.g., liver) to the patient. | Marrero et al. 2018 (ASSLD guideline) |
| Summary of clinical benefit | <ul style="list-style-type: none"> Transplantation is a highly effective, efficient therapy for early-stage HCC because it offers optimal treatment of both the underlying liver disease and the tumour, and is associated with excellent long-term survival rates for HCC within Milan criteria occurring in the setting of decompensated liver disease. | Marrero et al. 2018 (ASSLD guideline) |
| Summary of clinical risk | <ul style="list-style-type: none"> Transplantation is limited by the extreme shortage of available organ allografts and the need for lifelong immunosuppression. | Marrero et al. 2018 (ASSLD guideline) |
| Target population | Patients with early-stage liver tumours. | Marrero et al. 2018 (ASSLD guideline) |
| Thermal ablation | | |
| Description | Destruction or ablation of tumour cells can be achieved by the injection of chemical substances (ethanol, acetic acid, and boiling saline) or by modifying local tumour temperature (radiofrequency [RFA], microwave, laser, cryotherapy). The procedure can be done percutaneously with minimal invasiveness or during laparoscopy and is currently considered the best option for patients with BCLC stage A who are not candidates for surgical intervention. | Marrero et al. 2018 (ASSLD guideline) |
| Summary of clinical benefit | Several randomized controlled trials (RCTs) have confirmed the superiority of RFA over ethanol injection in terms of survival, particularly in BCLC stage A with nodules between 2 and 4 cm. Thermal ablative techniques have the best efficacy in tumours with maximum diameter less than | Marrero et al. 2018 (ASSLD guideline) |



| Intervention | Specification | Reference |
|---------------------------------|--|---------------------------------------|
| | 3 cm, although microwave ablation potentially provides better tumoral response than RFA. | |
| Summary of clinical risk/Limits | <ul style="list-style-type: none"> The recurrence rate after thermal ablation is similar to that observed after surgical resection, It has been shown that local recurrence is related to size and higher with tumours that are >3 cm HCC recurrence can occur at new sites in the liver in around 40% of individuals. | Marrero et al. 2018 (ASSLD guideline) |
| Target population | Patients with BCLC stage A who are not candidates for surgical intervention. | Marrero et al. 2018 (ASSLD guideline) |

7.0 Suggested profile and training for users

HepaSphere Microspheres must only be used by specialist physicians trained in vascular embolisation procedures.

8.0 Applicable Standards and Common Specifications

The list of all applied common specifications (CS), international standards harmonized under the medical device directives and/or the MDR, and relevant adopted monographs of the European pharmacopoeia is provided in Table 17.

Table 17. Applicable Standards and Common Specifications

| Standard Title | State of the Art Date/Version |
|--|-------------------------------|
| Medical devices – Information to be supplied by the manufacturer | NF EN 1041:2008+A1:2013 |
| Information Supplied by the Manufacturer with Medical Devices | ISO 20417:2021 |
| Medical devices - Symbols to be used with medical device labels, labelling and information to be supplied - Part 1: General requirements | NF EN ISO 15223-1:2017 |
| Medical devices - Symbols to be used with medical device labels, labelling and information to be supplied - Part 1: General requirements | ISO 15223-1:2021 |
| Medical devices — Symbols to be used with medical device labels, labelling, and information to be supplied — Part 2: Symbol development, selection and validation | NF EN ISO 15223-2:2010 |
| Guidance document Implant Card relating to the application of Article 18 Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices | MDCG 2019-8 v2 (2020) |
| Classification of Air Cleanliness, Clean rooms & Associated Controlled Environments. Part 1: Classification of air cleanliness | NF EN ISO 14644-1:2016 |



| Standard Title | State of the Art Date/Version |
|--|-------------------------------------|
| Sterilization of health care products -- Microbiological methods -- Part 1: Determination of a population of microorganisms on products | NF EN ISO 11737-1:2018 |
| Sterilization of medical devices - Microbiological methods - Part 2: Tests of sterility performed in the definition, validation and maintenance of a sterilization process | NF EN ISO 11737-2:2010 |
| Sterilization of medical devices - Microbiological methods - Part 2: Tests of sterility performed in the definition, validation and maintenance of a sterilization process | NF EN ISO 11737-2:2020 |
| Bacterial Endotoxins Assay | EP 2.6.14 and USP <85> |
| Transfusion and Infusion Assemblies and Similar Medical Devices | USP <161> |
| Sterilization of medical devices - Requirements for medical devices to be designated "STERILE" – Part 1: Requirements for terminally sterilized medical devices | NF EN 556-1:2002 |
| Sterilization of health care products -- Radiation -- Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices | NF EN ISO 11137-1:2016/A2:2019 |
| Sterilization of health care products - Radiation - Part 2: Establishing the sterilization dose | NF EN ISO 11137-2:2015 |
| Quality Systems – Medical Devices – Quality Management Systems. Requirements for Regulatory Purposes | ISO 13485:2016 EN ISO 13485:2016 |
| Medical Devices - Application of Risk Management to Medical Devices | NF EN ISO 14971:2019 |
| Biological Evaluation of Medical Devices – Part 1: Evaluation and testing | NF EN ISO 10993-1:2020 |
| Biological evaluation of medical devices -- Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity | NF EN ISO 10993-3:2014 |
| Biological evaluation of medical devices -- Part 4: Selection of tests for interactions with blood | NF EN ISO 10993-4:2018 |
| Biological evaluation of medical devices -- Part 5: Tests for in vitro cytotoxicity | NF EN ISO 10993-5:2010 |
| Biological Evaluation of Medical Devices – Part 6: Tests for local effects after implantation | NF EN ISO 10993-6:2017 |
| Biological evaluation of medical devices -- Part 10: Tests for irritation and skin sensitization | NF EN ISO 10993-10:2013 |
| Biological evaluation of medical devices -- Part 11: Tests for systemic toxicity | NF EN ISO 10993-11:2018 |
| Biological Evaluation of Medical Devices – Part 12: Sample preparation and reference materials | ISO 10993-12:2021 |
| Biological Evaluation of Medical Devices – Part 17: Methods for the Establishment of Allowable Limits for Leachable Substances | NF EN ISO 10993-17:2009 |
| Biological Evaluation of Medical Devices – Part 18: Chemical Characterization of Medical Device Materials within a Risk Management Process | NF EN ISO 10993-18: 2020 |
| Biological Evaluation of Medical Devices – Part 19: Physico-chemical, morphological and topographical characterization of materials | ISO/TS 10993-19:2020 |



| Standard Title | State of the Art Date/Version |
|--|------------------------------------|
| Biological evaluation of medical devices — Part 23: Tests for irritation | ISO 10993-23:2021 |
| Clinical investigation of medical devices for human subjects -- Good clinical practice | NF EN ISO 14155:2020 |
| Guidelines on Medical Devices – Clinical Evaluation – A Guide for Manufacturers and Notified Bodies under Directives 93/42/EEC | MEDDEV2.7.1 Rev. 4 (Jun 2016) |
| Guidance on Summary of safety and clinical performance | MDCG 2019-9 (August 2019) |
| Guidance on sufficient clinical evidence for legacy devices | MDCG 2020-6 (April 2020) |
| Guidance on PMCF plan template | MDCG 2020-7 (April 2020) |
| Guidance on Clinical evaluation assessment report template | MDCG 2020-13 (July 2020) |
| Post Market Clinical Follow-up studies | MEDDEV 2.12/2 Rev. 2 (Jan 2012) |
| Non-active surgical implants -- General requirements | NF EN ISO 14630:2013 |
| Injection containers and accessories — Part 6: Caps made of aluminum-plastics combinations for injection vials | NF EN ISO 8362-6:2011 |
| Containers – Plastic (vial) | USP <661> |
| Polyolefins (vial) | EP 3.1.3 |
| Elastomeric closures for injections (grey rubber stopper) | USP <381> |
| Rubber closures for containers for aqueous parenteral preparations, for powders and for freeze-dried powders (grey rubber stopper) | EP 3.2.9 |
| Medical Devices – Application of usability engineering to medical devices | <u>IEC 62366-1:2015/Amd 1:2020</u> |
| Packaging for Terminally Sterilized Medical Devices. Part 1: Requirements for materials, sterile barrier systems, and packaging systems. | NF EN ISO 11607-1:2020 |
| Packaging for Terminally Sterilized Medical Devices. Part 2: Validation requirements for forming, sealing and assembly processes | NF EN ISO 11607-2:2020 |
| Standard Practice for Performance Testing of Shipping Containers and Systems | ASTM D4169 - 16 |
| Standard Test Method for Detecting Gross Leaks in Medical Packaging by Internal Pressurization (Bubble Test) | ASTM F2096 - 11 (2019) |
| Standard Test Method for Seal Strength of Flexible Barrier Materials | ASTM F88/F88M - 15 |
| Standard Test Methods for Internal Pressurization Failure Resistance of Unrestrained Packages for Medical Applications | ASTM F1140/F1140M-13 (2020) |
| Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices | ASTM F1980 - 16 |
| Guidelines on a Medical Devices Vigilance System | MEDDEV 2.12/1 Rev. 8 (Jan 2013) |



9.0 References

1. AAMI/FDA Ad Hoc Risk Working Group. Postmarket risk management: A framework for incorporating benefit-risk assessments into correction and removal decisions. . In: Association for the Advancement of Medical Instrumentation; 2016
2. Akinwande O, Scoggins C, Martin RCG. Early experience with 70-150 µm irinotecan drug-eluting beads (M1-DEBIRI) for the treatment of unresectable hepatic colorectal metastases. *Anticancer research* 36: 3413-3418 (2016)
3. Albrecht KC, Aschenbach R, Diamantis I, Eckardt N, Teichgräber U. Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-µm doxorubicin-eluting microspheres. *J Cancer Res Clin Oncol.* 2021;147(1):23-32. doi:10.1007/s00432-020-03370-z
4. Aliberti C, Carandina R, Sarti D, et al. Hepatic Arterial Infusion of Polyethylene Glycol Drug-eluting Beads for Primary and Metastatic Liver Cancer Therapy. *Anticancer Res.* 2016;36(7):3515-3521.
5. Aliberti C, Fiorentini G, Muzzio PC, et al. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. *Anticancer Research* 2011; 31(12):4581-7.
6. Aliberti C, Tilli M, Benea G, et al. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: Preliminary results. *Anticancer Research* 2006 ;26 (5B):3793-5.
7. Amer et al. Intra-arterial chemoembolization with HepaSphere 50-100µm for patients with unresectable hepatocellular carcinoma: initial experience in Egyptian liver hospital. *Egypt J Radiol & Nuc Med* 2015
8. Basile A, Carrafiello G, Ierardi AM, et al. CIRSE Standards of Practice Guidelines: Quality improvement guidelines for hepatic transarterial chemoembolization. *Cardiovasc Interv Radiol* 2012"
9. Benson AB 3rd, D'Angelica MI, Abbott DE, et al. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. *J Natl Compr Canc Netw.* 2017;15(5):563-573.
10. Benson AB, et al. Epidemiology, disease progression, and economic burden of colorectal cancer. *Journal of Managed Care Pharmacy* 2007; 13(6): S5-18.
11. Bhutiani N, Akinwande O, Martin RCG. Efficacy and toxicity of hepatic intra-arterial drug-eluting (irinotecan) bead (DEBIRI) therapy in irinotecan-refractory unresectable colorectal liver metastases. *World Journal of Surgery*, May 2016, Volume 40, Issue 5, pp 1178–1190
12. Bishay VL, Maglione K, Khanna R, et al. Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy. *J Hepatocellular Carcinoma* 2014; 1:187-193.
13. Bonne et al. Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumors : preliminary results. *Radiol Oncol* 2017
14. Bruix J, Han K-H, Gores G, et al. Liver cancer: Approaching personalized care. *J Hepatology* 2015; 62(10):S144-S156."
15. Bruix J, Sherman M, Llovet J, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL conference. *J Hepatology* 2001; 35:421-430."
16. Bryant M, Dorn D, Zarzour J, et al. Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization. *HPB* 2013; DOI:10.1111/hpb.12149.
17. Cavalcante et al. Occurrence of Vascular Lake Phenomenon as a Predictor of Improved Tumor Response in HCC Patients That Underwent DEB-TACE. *Cardiovasc Intervent Radiol.* 2017 Jul; 40(7): 1044-1051
18. Cavalcante et al. Occurrence of Vascular Lake Phenomenon as a Predictor of Improved Tumor Response in HCC Patients That Underwent DEB-TACE. *Cardiovasc Intervent Radiol.* 2017 Jul; 40(7): 1044-1051



19. Chagas AL, Mattos AA, Carrilho FJ, et al. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. *Arq Gastroenterol.* 2020;57(suppl 1):1-20.
20. Chang JPE, Wong YJ, Yang WL, Lim KBL, Tan PS, Ho GH, Yip BCH, Li JW, Chong CH, Ong DEH, Chua TS, Vu CKF, Gwee KA, Ang TL, Tan CK. Chapter of Gastroenterologists professional guidance for management of patients with liver disease in Singapore during the COVID-19 pandemic. *Singapore Med J.* 2020 Dec;61(12):619-623.
21. Chen M., Xu R., Chen X., Mai Q. Hepatic fibrosis and short-term clinical efficacy after hepatic artery embolization for unresectable hepatocellular carcinoma using doxorubicin-eluting HepaSpheres. *Translational Cancer Research* 2020 9:3 (1361-1370).
22. Chen M., Xu R., Chen X., Mai Q. Hepatic fibrosis and short-term clinical efficacy after hepatic artery embolization for unresectable hepatocellular carcinoma using doxorubicin-eluting HepaSpheres. *Translational Cancer Research* 2020 9:3 (1361-1370).
23. Chiu SH, Chang PY, Shih YL, et al. Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma. *Drug Des Devel Ther.* 2020;14:5029-5041. Published 2020 Nov 17. doi:10.2147/DDDT.S266470
24. Cho JY, Kim SS, Lee YS, et al. Management of liver diseases during the pandemic of coronavirus disease-19. *Clin Mol Hepatol.* 2020 Jul;26(3):243-250.
25. Cong WM, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. *World J Gastroenterol.* 2016;22(42):9279-9287.
26. Crissien AM, frenette C. Current Management of Hepatocellular Carcinoma. *Gastroenterology.* 2014; 10(3): 153-161.
27. Dansey et al. Rapid aneurysm growth after transarterial chemoembolization. *J Vasc Surg Cases* 2015
28. Dansey et al. Rapid aneurysm growth after transarterial chemoembolization. *J Vasc Surg Cases* 2015
29. de Baere T, Guiu B, Ronot M, et al. Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry. *Cancers (Basel).* 2020;12(11):3405. Published 2020 Nov 17. doi:10.3390/cancers12113405
30. de Baere T, Tselikas L, Pearson E, et al. Interventional oncology for liver and lung metastases from colorectal cancer. The current state of the art. *Diagn Interv Imaging.* 2015;96(6):647-54.
31. de Baere T, Tselikas L, Pearson E, et al. Interventional oncology for liver and lung metastases from colorectal cancer. The current state of the art. *Diagn Interv Imaging.* 2015;96(6):647-54."
32. Dekervel J, Malenstein H, Vandecaveye V, et al. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up. *J Vasc Interv Radiol* 2013; DOI:10.1016/j.jvir.2013.10.017
33. Dorn D, Bryant M, Zarzour J, et al. Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function. *HPB* 2013; DOI:10.1111/hpb.12194.
34. Dorn D, Bryant M, Zarzour J, et al. Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function. *HPB* 2013; DOI:10.1111/hpb.12194.
35. Duan et al. Superselective chemoembolization of HCC: comparison of short-term safety and efficacy between drug-eluting LC Beads, QuadraSpheres, and conventional ethiodized oil emulsion. *Radiol* 2015
36. Duan et al. Superselective chemoembolization of HCC: comparison of short-term safety and efficacy between drug-eluting LC Beads, QuadraSpheres, and conventional ethiodized oil emulsion. *Radiol* 2015
37. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *Journal of Hepatology* 2018. vol. 69:182–236.
38. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. *Euro J of Cancer* 2012; 48:599-64
39. Eichler K, Zangos S, Mack MG, et al. First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). *IJO* 2012; 41(4):1213-1220.



40. Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. *World Journal of Gastroenterology* 2018 24:2 (161-169).
41. Farid K., Elalfy H., Abo El-khair S.M., et al. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients. *Expert Review of Gastroenterology and Hepatology* 2020 14:12 (1203-1214)
42. Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI®) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: Final results of a phase III study. *Anticancer Research* 2012; 32(4):1387-95. Erratum in: *Anticancer Research* 2013; 33(11):5211.
43. Fiorentini G, Aliberti C, Turrisi G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Results of a phase II clinical study. *In Vivo* 2007; 21(6):1085-91.
44. Gaba RC, Lokken RP, Hickey RM, et al. Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. *J Vasc Interv Radiol* 2017; 28:1210–1223.
45. Gaba RC, Mendoza-Elias N, Morrison JD, et al. Decision Making for Selection of Transarterial Locoregional Therapy of Metastatic Neuroendocrine Tumors. *Semin Intervent Radiol* 2017;34:101–108.
46. Gadaleta CD, Catino A, Ranieri G, et al. Single-step therapy - feasibility and safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic malignancies. *in vivo* 2009; 23:813-820.
47. Ginsburg M, Zvin SP, Wroblewski K et al. Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation. *J Vasc Interv Radiol*. 2015 Mar;26(3):330-41.
48. Gjoreski A, Popova-Jovanovska R, Eftimovska-Rogac I, Vejseli J. Safety Profile and Efficacy of Chemoembolization with Doxorubicin - Loaded Polyethylene Glycol Microspheres in Patients with Hepatocellular Carcinoma. *Open Access Maced J Med Sci*. 2019;7(5):742-746. Published 2019 Mar 11. doi:10.3889/oamjms.2019.179
49. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. *Ann Intern Med*. 1994;121:200-206.
50. Greco G, Cascella T, Facciorusso A, et al. Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma. *World J Radiol*. 2017;9(5):245-252. doi:10.4329/wjr.v9.i5.245
51. Grosso M, Vignali C, Quaretti P, et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. *Cardiovasc Intervent Radiol* 2008 Nov-Dec;31(6): 1141-1149.
52. Habibollahi P, Hunt S, Gade T, et al. The Impact of Bridging LRT on Survival in Patients Listed for Liver Transplantation. *Cardiovasc Intervent Radiol*. 2018 Jan;41(1):112-119.
53. Habibollahi P, Shamchi SP, Choi JM, et al. Association of Complete Radiologic and Pathologic Response following Locoregional Therapy before Liver Transplantation with Long-Term Outcomes of Hepatocellular Carcinoma: A Retrospective Study. *J Vasc Interv Radiol* 2019; 30:323–329.
54. HAS - Guide affection longue durée. ALD 30 - Tumeur maligne, affection maligne du tissu lymphatique ou hématopoïétique - Cancer primitif du foie. Novembre 2010
55. HAS - Guide Medecin - ALD - Cancer colorectal Adénocarcinome - janvier 2012
56. HAS - Guide Patient - affection longue durée. La prise en charge du cancer du foie. Decembre 2010
57. HAS - Guide Patient - ALD - Cancer colorectal Adénocarcinome - Mars 2010
58. Haug J, Runback J, Herman C. Rare pulmonary infarction after superior epigastric artery chemoembolization of unresectable hepatocellular carcinoma. *Radiology Case Reports* 2012; 7:3.
59. Heimbach JK, Kulik LM, Finn RS, et al. AASLD Guidelines for the Treatment of Hepatocellular Carcinoma. *Hepatology* 2018; 67(1): 358-380.



60. Hetta WM, Shebria N. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres. *Egypt J Radiol Nuc Med* 2014; DOI 10.1016/j.ejnm.2014.04.021.
61. Hiraki et al. Transcatheter arterial embolization of hypervascular tumors with HepaSpheres: prospective multicenter open label clinical trial of microspheres in Japan. *Jpn J Radiol* 2015
62. Huppert P, Wenzel T, Wietholtz H. Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. *Cardiovasc Intervent Radiol* 2013; DOI:10.1007/s00270-013-0632-0.
63. Idilman I, Peynircioglu B, Cil B, et al. Transarterial chemoembolization for treatment of hepatocellular carcinoma: a single center experience. *Turk J Gastroenterol* 2012; 24(2):141-147.
64. Idilman I, Peynircioglu B, Cil B, et al. Transarterial chemoembolization for treatment of hepatocellular carcinoma: a single center experience. *Turk J Gastroenterol* 2012; 24(2):141-147.
65. Jarzabek M, Jargietto T, Wolski A, et al. Drug-eluting microspheres transarterial chemoembolization (DEM TACE) in patients with liver metastases. Pilot Study. *Pol J Radiol* 2011; 76(3):26-32.
66. JE Cruz, R Saksena, SK Jabbour et al. The Power of Genes: A Case of Unusually Severe Systemic Toxicity After Localized Hepatic Chemoembolization With Irinotecan-Eluted Microspheres for Metastatic Colon Cancer. *Annals of Pharmacotherapy*, Volume: 48 issue: 12, page(s): 1646-1650, September 8, 2014
67. Kallini JR, Gabr A, Ali R, et al. Pretransplant Intra-arterial Liver-Directed Therapy Does Not Increase the Risk of Hepatic Arterial Complications in Liver Transplantation: A Single-Center 10-Year Experience. *Cardiovasc Intervent Radiol* (2018) 41:231–238.
68. Kim K.W., Van Den Abbeele A.D. Evolution of transarterial chemoembolization for the treatment of liver cancer. *Radiology* 2019 293:3 (704-706).
69. Klass D, Owen D, Buczkowski A, et al. The effect of doxorubicin loading on response and toxicity with drug-eluting embolization in resectable hepatoma: A dose escalation study. *Anticancer Res* 2014; 34:3597-3606.
70. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC), Goyang, Korea. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. *Korean J Radiol*. 2019;20(7):1042-1113.
71. Kucukay et al. A single-center retrospective comparison of doxorubicin-loaded HepaSpheres transarterial chemoembolization with conventional transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. *J Vasc Intervent Radiol* 2015
72. Kucukay et al. A single-center retrospective comparison of doxorubicin-loaded HepaSpheres transarterial chemoembolization with conventional transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. *J Vasc Intervent Radiol* 2015
73. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. *Cardiovasc Intervent Radiol*. 2010;33(1):41-52. doi:10.1007/s00270-009-9711-7
74. "Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. *CVIR On Line First*, Nov 2009"
75. Lee M, Chung JW, Lee KH, et al. Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis. *J Vasc Interv Radiol*. 2017;28(4):502-512. doi:10.1016/j.jvir.2016.08.017
76. Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. *J Hepatol*. 2016;64(5):1090-1098. doi:10.1016/j.jhep.2016.01.012
77. Leoni CJ, Potter JE, Rosen MP, Brophy DP, Lang EV. Classifying Complications of Interventional Procedures: A Survey of Practicing Radiologists. *Journal of Vascular and Interventional Radiology*. 2001;12(1):55-59.
78. Lewis A.L., Hall B. Toward a better understanding of the mechanism of action for intra-arterial delivery of irinotecan from DC Bead(TM) (DEBIRI). *Future Oncology* 2019 15:17 (2053-2068).
79. Lezzi R, Marsico VA, Guerra A et al. Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study. *Cardiovasc Intervent Radiol*. 2015 Dec;38(6):1523-31.



80. Li S, Feng X, Cao G, et al. Prognostic significance of inflammatory indices in hepatocellular carcinoma treated with transarterial chemoembolization: A systematic review and meta-analysis. *PLoS One*. 2020 Mar 26;15(3):e0230879.
81. Liu YS, Lin CY, Chuang MT, et al. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. *BMC Gastroenterology* (2018) 18:124
82. Llovet J, Di Bisceglie A, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. *J Nat Cancer Inst* 2008; 100(10): 698-711.
83. Malagari K, Moschouris H, Kiakidis T, et al. Five-Years Outcome Analysis of 142 Consecutive Hepatocellular Carcinoma Patients Treated with Doxorubicin Eluting Microspheres 30-60 µm: Results from a Single-Centre Prospective Phase II Trial. *Cardiovasc Intervent Radiol*. 2019;42(11):1551-1562. doi:10.1007/s00270-019-02260-3
84. Malagari K, Pomoni A, Filippiadis D et al. Chemoembolization of hepatocellular carcinoma with HepaSpheres™. *Hep Onco*. 2015 May; 2 (2).
85. Malagari K, Pomoni M, Moschouris H, et al. Chemoembolization of hepatocellular carcinoma with HepaSpheres 30-60µ. Safety and efficacy study. *Cardiovasc Intervent Radiol* 2013; DOI:10.1007/s00270-013-0777-x.
86. Malagari K, Pomoni M, Moschouris H, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. *Cardiovasc Intervent Radiol*. 2012;35(5):1119-1128. doi:10.1007/s00270-012-0394-0
87. Maluccio MA, Covey AM, Schubert J, et al. Treatment of Metastatic Sarcoma to the Liver With Bland Embolization. *Cancer*. 2006 Oct 1;107(7):1617-23.
88. Mansour et al. Transarterial chemoembolization using drug eluting microspheres in refractory colorectal liver metastases with 18F-FDG PET/CT follow-up to assess therapeutic response. *Egypt J Radiol Nuc Med* 2016; 47:1467-72
89. Marrero J.A, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2018; 68(2): 723-750.
90. Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead irinotecan (DEBIRI®) in unresectable colorectal liver metastases refractory to systemic chemotherapy: Results of a multi-institutional study. *Annals Surg Onc* 2011; 18(1):192-8.
91. Martin RC, Scoggins CR, Tomalty D, et al. Irinotecan drug-eluting beads in the treatment of chemo-naïve unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: Results of pharmacokinetics and phase I trial. *J Gastro Surg* 2012;16(8):1531-8.
92. Martin RC, Howard J, Tomalty D, et al. Toxicity of irinotecan eluting beads in the treatment of hepatic malignancies: Results of a multi-institutional registry. *Cardiovasc Intervent Radiol* 2010; 33(5):960-6.
93. McDonald JH. *Handbook of Biological Statistics*. 3rd ed. Baltimore, MD: Sparky House Publishing; 2014.
94. Moschouris H, Malagari K, Papadaki M, et al. mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization. *Diagn Interv Radiol* 2013; DOI:10.5152/dir.2013.13282.
95. Moschouris H, Malagari K, Papadaki M, et al. mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization. *Diagn Interv Radiol* 2013; DOI:10.5152/dir.2013.13282.
96. Narayanan G, Barbery K, Suthar R, et al. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. *Anticancer Research*, 2013; 33(5):2077-83.
97. Notice patient - DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion - Base de données publique des médicaments
98. Notice patient - IRINOTECAN HOSPIRA 20 mg/ml, solution à diluer pour perfusion - Base de données publique des médicaments
99. Nouri Y.M., Kim J.H., Yoon H.-K., et al. Update on transarterial chemoembolization with drug-eluting microspheres for hepatocellular carcinoma. *Korean Journal of Radiology* 2019 20:1 (34-49)
100. Osuga K, Hori S, Hiraishi K, et al. Bland embolization of hepatocellular carcinoma using superabsorbent polymer microspheres. *Cardiovasc Intervent Radiol* 2008; 31(6): 1108-1116.
101. Osuga K, Hori S, Hiraishi K, et al. Bland embolization of hepatocellular carcinoma using superabsorbent polymer microspheres. *Cardiovasc Intervent Radiol* 2008; 31(6): 1108-1116



102. Pereira PL, Iezzi R, Manfredi R, et al. The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis. *Cardiovasc Intervent Radiol*. 2021;44(1):50-62. doi:10.1007/s00270-020-02646-8
103. Pua U. Bradycardia associated with drug-eluting beads loaded with irinotecan (DEBIRI) infusion for colorectal liver metastases. *Cardiovasc Intervent Radiol* 2013; 36:864–866.
104. Pwint TP, et al. Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver. *Seminars in Oncology* 2010; 37(2):149-59
105. Ranieri et al. A pilot study employing hepatic intra-arterial irinotecan injection of drug-eluting beads as salvage therapy in liver metastatic colorectal cancer patients without extrahepatic involvement: the first southern Italy experience. *OncoTargets & Therapy* 2016; 9:7527-35
106. Résumé des caractéristiques du produit - DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion - Base de données publique des médicaments
107. Résumé des caractéristiques du produit - IRINOTECAN 20 mg/ml, solution à diluer pour perfusion - Base de données publique des médicaments
108. Révision de catégories de dispositifs médicaux : Implants d'embolisation artérielle (pour fistule artérioveineuse, tumeur, anévrisme) : Indications craniocéphaliques et vertébro-médullaires. 2011 Haute Autorité de Santé (HAS)
109. Révision de catégories de dispositifs médicaux : Implants d'embolisation artérielle (pour fistule artérioveineuse, tumeur, anévrisme) : Indications en dehors de la topographie craniocéphalique. 2011 Haute Autorité de Santé (HAS)
110. Richardson A, Laurence J, Lam V, et al. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: Systematic review. *JVIR* 2013; 24:1209-1217.
111. Richter G, Radeleff B, Stroszczyński C, et al. Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study. *Cardiovasc Intervent Radiol*. 2018;41(4):587-593. doi:10.1007/s00270-017-1839-2
112. S Carter, II Martin, CG Robert. Drug-eluting bead therapy in primary and metastatic disease of the liver. *International Hepato-Pancreato-Biliary Association (HPB)*, Volume 11, Issue 7, November 2009, Pages 541–550
113. Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology Clinical Practice Guidelines. *Journal of Vascular and Interventional Radiology*. 2003;14(9):S199-S202.
114. Salvatore L, Aprile G, Arnoldi E, et al. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). *ESMO Open* 2017;2:e000147. doi:10.1136/esmoopen-2016-000147
115. Sapir E, Tao y, Schipper MJ, et al. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. *Int J Radiat Oncol Biol Phys*. 2018 Jan 1;100(1):122-130.
116. Shiina S, Gani RA, Yokosuka O, et al. APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19. *Hepatol Int*. 2020 Dec;14(6):920-929.
117. Skowasch M, Schneider J, Otto G, et al. Midterm follow-up after DC-BEAD™-TACE of hepatocellular carcinoma (HCC). *Eur J Radiol*. 2012;81(12):3857-3861. doi:10.1016/j.ejrad.2012.07.002
118. Stambo GS, Cragan D. Response rates of hepatocellular carcinoma and hepatic colorectal cancer metastases to drug eluting bead regional liver therapy. *Hepatoma Res* 2017;3:141-8.
119. Sun et al. Chemoembolization of liver cancer with drug-loading microsphere 50-100µm. *Oncotarget* 2017;8(3):5392-5399.
120. Tanaka T., Sato T., Nishiofuku H., et al. Selective TACE with irinotecan-loaded 40 µm microspheres and FOLFIRI for colorectal liver metastases: Phase i dose escalation pharmacokinetic study. *BMC Cancer* 2019 19:1 Article Number 758.
121. Torres OJ, Marques MC, Santos FN, et al. BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES. *Arq Bras Cir Dig*. 2016;29(3):173-179.
122. U.S. Food & Drug Administration. Factors to consider when making benefit-risk determinations in medical device premarket approval and de novo



- classifications: Guidance for industry and Food and Drug Administration staff. In: Health CfDaR, ed. Rockville, MD: US Food & Drug Administration; 2019
123. Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Annals of Oncology* 27: 1386–1422, 2016 doi:10.1093/annonc/mdw235"
124. van Dam PJ, van der Stok EP, Teuwen LA, et al. International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. *Br J Cancer*. 2017;117(10):1427-1441.
125. Van Malenstein, H., Maleux, G., Vandecaveye, V., Heye, S., Laleman, W., Van Pelt, J., Vaninbrookx, J., Nevens, F., Verslype, C. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. *Onkologie* (2011) 34:368-376.
126. Van Malenstein, H., Maleux, G., Vandecaveye, V., Heye, S., Laleman, W., Van Pelt, J., Vaninbrookx, J., Nevens, F., Verslype, C. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. *Onkologie* (2011) 34:368-376.
127. Vasanani R, Ginsburg M, Ahmed O et al. Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplant. *HepatoBiliary Surg Nutr* 2016 ; 5(3):225-33
128. Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in *Ann Oncol*. 2019 May 1;30(5):871-873] [published correction appears in *Ann Oncol*. 2019 May;30(5):871-873]. *Ann Oncol*. 2018;29(Suppl 4):iv238-iv255.
129. Vogl TJ, Pereira PL, Helmberger T, et al. [Updated S3 Guidelines - Diagnosis and Treatment of Colorectal Carcinoma: Relevance for Radiological Diagnosis and Intervention]. *Rofo*. 2019;191(4):e2.
130. Wang D, Louie J, Sze D. Intra-Arterial therapies for metastatic colorectal cancer. *Semin Intervent Radiol* 2013; 30:12–20.
131. Wang DS, Louie JD, Sze DY. Intra-Arterial Therapies for Metastatic Colorectal Cancer. *Semin Intervent Radiol* 2013;30:12–20
132. Wei G., Yang J. Advances in the treatment of hepatocellular carcinoma using drug-eluting beads. *Journal of Interventional Medicine* 2020 3:3 (122-127)
133. Wu L, Xu P, Rao S, et al. ADCtotal Ratio and D Ratio Derived From Intravoxel Incoherent Motion Early After TACE Are Independent Predictors for Survival in Hepatocellular Carcinoma. *J. Magn. Reson. Imaging* 2017;46:820–830.
134. Wu M, Gao S, Song H et al. Percutaneous thermal ablation combined with simultaneous transarterial chemoembolization for hepatocellular carcinoma ≤5 cm. *J Can Res Ther* 2019;15:766-72.
135. Yamaguchi T., Seki T., Komemushi A., et al. Acute necrotizing pancreatitis as a fatal complication following dc bead transcatheter arterial chemoembolization for hepatocellular carcinoma: A case report and review of the literature. *Molecular and Clinical Oncology* 2018 9:4 (403-407).
136. Zener R, Yoom H, Ziv E, et al. Outcomes After Transarterial Embolization of Neuroendocrine Tumor Liver Metastases Using Spherical Particles of Different Sizes. *Cardiovasc Intervent Radiol* (2019) 42:569–576.
137. Zhang T-Q, Huang Z-M, Shen J-X, et al. Safety and effectiveness of multi-antenna microwave ablation-oriented combined therapy for large hepatocellular carcinoma. *Ther Adv Gastroenterol* 2019, Vol. 12: 1–14,
138. Zurstrassen et al. Safety and efficacy of HepaSpheres 50-100 µm in the treatment of hepatocellular carcinoma. *Min Invasive Ther App Tech* 2017



10.0 List of abbreviations

| Abbreviation/Acronym | Definition |
|----------------------|---------------------------------|
| BCLC | Barcelona Clinic Liver Cancer |
| CR | Complete tumor Response |
| DCR | Disease Control Rate |
| DEM | Drug Eluting Microspheres |
| EEC | European Economic Community |
| ER | Essential Requirements |
| EU | European Union |
| HCC | Hepatocellular Carcinoma |
| HS | HepaSphere Microspheres |
| IFU | Instruction For Use |
| Lm | Liver metastases |
| LT | Liver Transplantation |
| mCRC | Metastatic Colorectal Cancers |
| MDR | Medical Device Regulation |
| MR | Magnetic Resonance |
| ORR | Objective tumor Response Rate |
| OS | Overall Survival |
| PFS | Progression Free Survival |
| PMCF | Post Market Clinical Follow-up |
| PMS | Post Market Surveillance |
| QS | QuadraSphere Microspheres |
| SD | Similar Device |
| SOA | State-of-the-art |
| TACE | Transarterial ChemoEmbolization |



11.0 Revision History

| SSCP Revision | ECN Number | Date Issued | Change description | SSCP Author/PRRC | Revision Validated by the Notified Body |
|---------------|------------|-------------|--|--|--|
| 001 | PAR4219 | 21-Feb-2023 | Initial release of the Summary of Safety and Clinical Performance (SSCP) for the HepaSphere Microspheres | Author: Lionel EkeDi Ngando Person Responsible for Regulatory Compliance: Rosène Amossé | <input checked="" type="checkbox"/> Yes Validation language: English <input type="checkbox"/> No |



Intentionally Left Blank



Summary of Safety and Clinical Performance (SSCP)

Language: English

This document is a summary of safety and clinical performance (SSCP) for the HepaSphere Microspheres intended for public access to the main aspects related to device safety and performance. The information presented in this SSCP is intended for patients or lay persons. A more extensive summary of device safety and clinical performance is provided for healthcare professionals.

The SSCP is not intended to give general advice on the treatment of a medical condition. Please contact your doctor or healthcare professional if you have questions about your medical condition or about the use of the HepaSphere Microspheres in your situation. This SSCP is not intended to replace an Implant Card or the Instructions for Use (IFU) to provide information on the safe use of the HepaSphere Microspheres.

**1.0 Device Identification and General Information**

HepaSphere Microspheres were first CE-marked by Biosphere Medical in 2004 for the embolization of liver cancer and metastases to the liver. Chemoembolization with HepaSphere Microspheres loaded with doxorubicin for liver cancer and liver metastases received CE-mark in 2007. More recently, HepaSphere Microspheres loaded with irinotecan has been approved for embolization of metastatic colorectal cancer (mCRC) to the liver (CE-mark in 2015).

1.1 Device trade name(s):

HepaSphere® Microspheres is the device trade name covered by this SSCP. The device model numbers are listed in Table 1.

Table 1 Devices Included in this SSCP

| Nominal dry size (µm) | Size after Reconstitution (µm) | Colour code | Reference code by weight | |
|-----------------------|--------------------------------|-------------|--------------------------|------------|
| | | | 25 mg vial | 50 mg vial |
| 20-40* | 80-160 | Grey* | V125HS* | V150HS* |
| 30-60 | 120-240 | Orange | V225HS | V250HS |
| 50-100 | 200-400 | Yellow | V325HS | V350HS |
| 100-150 | 400-600 | Blue | V525HS | V550HS |
| 150-200 | 600-800 | Red | V725HS | V750HS |

*HepaSphere Q2 Microspheres is also a brand name of the 20-40µm size range

1.2 Manufacturer Information

The name and address of the manufacturer of the HepaSphere Microspheres are provided in Table 2.

Table 2 Manufacturer Information

| Manufacturer Name | Address of Manufacturer |
|------------------------|---|
| Biosphere Medical S.A. | Parc des Nations – Paris Nord II, 383, Rue de la Belle Etoile, 95700 Roissy en France, France |

1.3 Basic UDI-DI

The basic Unique Device Identifier (UDI) with Device Identification (DI) key is 088445048755E9.



1.4 Year of EU Market Introduction

The HepaSphere Microspheres were first placed on the EU market in 2004.

2.0 Intended Use of the Device

2.1 Intended Purpose

HepaSphere Microspheres are designed for controlled, targeted embolization. In other words, the spheres are implants. They are used to block blood flow in aimed vessels. They are used by doctor to treat liver cancers.

2.2 Indication(s) and Intended Patient Groups

HepaSphere Microspheres are indicated for use in embolization of blood vessels with or without delivery of doxorubicin HCl for therapeutic or preoperative purposes in the following procedures:

- Embolization of hepatocellular carcinoma
- Embolization of metastases to the liver

HepaSphere Microspheres loaded with irinotecan are indicated for use in:

- Embolization of metastatic colorectal cancer (mCRC) to the liver

2.3 Contraindications:

HepaSphere Microspheres have the contraindications listed below. In summary, the device is contraindicated if the treatment cannot be supported by the patient, treatment is unsafe due to other patient conditions, cancer is in the lungs, heart, or central nervous system, or if the patient has a known allergy to the device materials.

- Patients intolerant to vascular occlusion procedures
- Vascular anatomy or blood flow precluding correct catheter placement or embolic injection
- Presence or suspicion of vasospasm
- Presence or likely onset of haemorrhage



- Presence of severe atheromatous disease
- Presence of collateral vessel pathways potentially endangering normal territories during embolization
- High flow arteriovenous shunts or fistulae with luminal diameter greater than the selected size of HepaSphere Microspheres
- Vascular resistance peripheral to the feeding arteries precluding passage of HepaSphere Microspheres into the lesion
- Do not use in pulmonary vasculature, coronary and central nervous system vasculature
- Known sensitivity to poly vinyl alcohol-co-sodium acrylate

3.0 Device Description

HepaSphere Microspheres are an implant. Each microsphere is a small sphere. It is about the size of a grain of sand. It is made of acrylic copolymer. This material is safe for use in the human body. The spheres can absorb and release anticancer drugs.

3.1 Materials/Substances in Contact with Patient Tissues

Only the spheres composed of acrylic copolymer will be in contact with your blood vessels. The spheres are a life-long permanent implant.

Table 3. Contact with Materials/Substances

| Material | Duration of exposure | Level of patient exposure |
|---------------------------------------|----------------------|---------------------------|
| Poly vinyl alcohol-co-sodium acrylate | Permanent | ≤ 50 mg |

3.2 Operating Principals/Mode of Action

The general procedure steps and operating principle in an embolization procedure are listed in Table 4.

Table 4. Procedure and Operating Principle

| Embolization Procedure | Description |
|------------------------|--|
| Step 1 | The treatment consists in blocking the target vessels with spheres mixed with anti-cancer drugs. It starts with a small cut in your thigh or your forearm. |
| Step 2 | Using special equipment, the doctor passes a thin tube into a vessel in your thigh or your forearm. |
| Step 3 | Then the doctor guides the tube near the location of the target vessels. |



| Embolization Procedure | Description |
|------------------------|---|
| Step 4 | At this location, the injection of the drug-loaded spheres begins. |
| Step 5 | The small spheres will block the blood flow around the targeted cancer and release the anti-cancer drug. |
| Operating Principle | <p>The small spheres block the vessels around the targeted cancer. Then, the blood flow cannot feed the cancer anymore. In addition, the spheres release the anti-cancer drugs. The lack of blood and the anti-cancer drugs result in the cancer decrease.</p> <p>In all cases, the spheres remain in the body for the lifetime of the patient. The doctor removes the tube after treatment. The doctor will apply a pressure point to stop any bleeding. The treatment is usually an outpatient procedure. The patient may be back at home within 4 to 23 hours after treatment.</p> |

3.3 Accessories

Other accessories used with the HepaSphere Microspheres during the procedure include sterile microcatheters and syringes. These accessories allow your doctor to reach the target vessel in your body and deliver the spheres to the treatment area.

3.4 Devices/Materials Used in Combination

Chemotherapy agents may be used in combination with the HepaSphere Microspheres during the procedure. These may include agents such as doxorubicin or irinotecan. Contact your doctor for more information on these agents.

4.0 Risks and Warnings

Contact your doctor if you believe that you are experiencing side effects related to the device or its use, or if you are concerned about risks. This document is not intended to replace a meeting with your doctor.

4.1 Residual Risks and Undesirable Effects

Potential complications and side effects may be associated with the HepaSphere Microspheres. These are listed in Table 5 and Table 6.



Table 5. Listing of Potential Complications

| Product Configuration | Potential Complications |
|---|--|
| HepaSphere Microspheres HepaSphere Q2 Microspheres | <p>Vascular embolization is a high-risk procedure. Complications may occur at any time during or after the procedure, and may include, but are not limited to, the following:</p> <ul style="list-style-type: none"> • Post-embolization syndrome (such as nausea, vomiting, pain, fever) • Fatigue and loss of appetite • Hypertension (high blood pressure) • Liver disorders or failure (including liver enzyme anomalies and ascites) • Complications related to catheterization (e.g., haematoma at the site of entry, clot formation at the tip of the catheter and subsequent dislodgement, and nerve and/or circulatory injuries which may result in leg injury) • Vessel or lesion rupture and hemorrhage (bleeding) • Vasospasm (constriction of vessels) • Recanalisation (blood flow through treated region) • Allergic reaction to medications (e.g., analgesics) • Allergic reaction to non-ionic contrast media or embolic material • Undesirable reflux or passage of HepaSphere Microspheres into normal arteries adjacent to the targeted lesion or through the lesion into other arteries or arterial beds, such as the internal carotid artery, pulmonary, or coronary circulation • Pulmonary embolism due to arteriovenous shunting • Pleural effusion • Ischemia at an undesired location, including ischemic stroke, ischemic infarction (including myocardial infarction), and tissue necrosis • Capillary bed occlusion and tissue damage (cholecystitis, cholangitis, pancreatitis) • Paralysis resulting from untargeted embolization or ischemic injury from adjacent tissue oedema • Blindness, hearing loss, and loss of smell • Foreign body reactions necessitating medical intervention • Infection necessitating medical intervention (including liver abscess) • Death |

**Table 6. Summary of Side Effects**

| Side effect | Description | Reported Frequency |
|-----------------------------------|---|----------------------------|
| Post-embolisation syndrome | Pain, fever, nausea, and tiredness. | Four out of 10 cases |
| Allergic reactions | Allergic reaction to gelatin, or to other products and drugs used during the treatment. | Less than one in 100 cases |
| Risks related to catheter placing | Damage to the blood vessel, bleeding at the cutting site or infection. | Less than one in 100 cases |
| Non-targeted embolisation | The small spheres may unwillingly block the blood flow of other vessels. | One in 100 cases |

4.2 Warnings and Precautions

Table 7 lists the warning and precautions for the HepaSphere Microspheres.

Table 7. Listing of Warnings and Precautions

| Product Configuration | Labeling |
|---|---|
| HepaSphere Microspheres HepaSphere Q2 Microspheres | Warnings <ul style="list-style-type: none"> HepaSphere Microspheres size must be chosen after consideration of the arteriovenous angiographic appearance. HepaSphere Microspheres size should be selected both to be appropriate for the size of the vessel feeding the target and to prevent passage from artery to vein. Some of the HepaSphere Microspheres may be slightly outside of the range, so the physician should be sure to carefully select the size of HepaSphere Microspheres according to the size of the target vessels at the desired level of occlusion in the vasculature and after consideration of the arteriovenous angiographic appearance. Because of the significant complications of untargeted embolization, extreme caution should be used for any procedures involving the extracranial circulation encompassing the head and neck, and the physician should carefully weigh the potential benefits of using embolization against the risks and potential complications of the procedure. These complications can include blindness, hearing loss, loss of smell, paralysis, and death. Serious radiation induced skin injury may occur to the patient due to long periods of fluoroscopic exposure, large patient, angled x-ray projections and multiple image recording runs or radiographs. Refer to your facility's clinical protocol to ensure the proper radiation |



| Product Configuration | Labeling |
|-----------------------|--|
| | <p>dose is applied for each specific type of procedure performed.</p> <ul style="list-style-type: none">• Onset of radiation injury to the patient may be delayed. Patients should be counselled on potential radiation effects, what to look for and whom to contact if symptoms occur.• HepaSphere Microspheres MUST NOT be reconstituted in sterile water for injection. Reconstitution in sterile water results in extensive swelling that renders the injection of HepaSphere Microspheres very difficult or may prevent injection.• Do not reconstitute HepaSphere Microspheres with Lipiodol / Ethiodol.• Pay careful attention for signs of untargeted embolization. During injection carefully monitor patient vital signs to include SaO₂ (e.g., hypoxia, CNS changes). Consider terminating the procedure, investigating for possible shunting, or increasing Microspheres size if any signs of untargeted embolization occur or patient symptoms develop.• Consider upsizing the Microspheres if angiographic evidence of embolization does not quickly appear evident during injection of the Microspheres. <p><u>Warnings about use of small microspheres:</u></p> <ul style="list-style-type: none">• Careful consideration should be given whenever use is contemplated of embolic agents that are smaller in diameter than the resolution capability of your imaging equipment. The presence of arteriovenous anastomoses, branch vessels leading away from the target area or emergent vessels not evident prior to embolization can lead to untargeted embolization and severe complications.• Microspheres smaller than 100 microns are more likely to terminate circulation to distal tissue. Greater potential of ischemic injury results from use of smaller sized microspheres and consideration must be given to the consequence of this injury prior to embolization. The potential consequences include swelling, necrosis, paralysis, abscess and/or stronger post-embolization syndrome.• Post embolization swelling may result in ischemia to tissue adjacent to target area. Care must be given to avoid ischemia of intolerant, non-targeted tissue such as nervous tissue. <p>Precautions</p> <ul style="list-style-type: none">• HepaSphere Microspheres must only be used by physicians trained in vascular embolization procedures. The size and quantity of microspheres must be carefully selected according to the lesion to be treated and the potential presence of shunts. Only the physician can decide the most appropriate time to stop the injection of HepaSphere |

| Product Configuration | Labeling |
|-----------------------|--|
| | <p>Microspheres.</p> <ul style="list-style-type: none"> • Do not use if the vial, cap, or pouch appear damaged. • For single patient use only - Contents supplied sterile - Never reuse, reprocess, or resterilize the contents of a vial that has been opened. Reusing, reprocessing or resterilizing may compromise the structural integrity of the device and or lead to device failure, which in turn may result in patient injury, illness or death. Reusing, reprocessing or resterilizing may also create a risk of contamination of the device and or cause patient infection or cross infection including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device may lead to injury, illness or death of the patient. All procedures must be performed according to accepted aseptic technique. • HepaSphere Microspheres MUST NOT be used in their original dry state. They must be reconstituted before use. • HepaSphere Microspheres swell in aqueous solution. The magnitude of swelling depends on the ionic concentration of the solution. Refer to section “SWELLING BEHAVIOR” of the product’s Instructions For Use (IFU). • HepaSphere Microspheres are compressible and can be injected easily through microcatheters. However, injection of the HepaSphere Microspheres before they are fully expanded could result in failure to reach the intended embolization target and possible embolization of a larger tissue area. • Note: Maximum recommended concentration of doxorubicin HCl is 5mg/ ml. Concentrations of doxorubicin HCl above 5mg/ml substantially increase the solution viscosity and make it difficult to handle with HepaSphere Microspheres. Maximum recommended concentration of irinotecan is 20 mg/ml. • Patients with known allergies to non-ionic contrast media may require corticosteroids prior to embolization. Additional evaluations or precautions may be necessary in managing periprocedural care for patients with the following conditions: <ul style="list-style-type: none"> ○ Bleeding diathesis or hypercoagulative state ○ Immunocompromise • Note: If loading HepaSphere Microspheres with doxorubicin HCl or irinotecan, refer to the appropriate drug IFU for information concerning contraindications, warnings, precautions, potential complications, dosage, and patient management before use. |



4.3 Magnetic Resonance Imaging

There is no risk with magnetic resonance imaging (MRI). The spheres are considered MRI safe.

4.4 Other Relevant Safety Aspects

There have been no product recalls or field actions related to the spheres.

4.5 Patient Implant Card

An implant card has been provided to you by the hospital after your treatment. You must keep it forever.

5.0 Summary of Clinical Evaluation and Postmarket Clinical Follow-up (PMCF)

Doctors in Europe and worldwide have used HepaSphere Microspheres for more than 15 years. Table 8 summarizes the clinical safety and performance information. These results are based on 30 clinical papers reporting use in patients to treat liver cancer.

Table 8. Safety and Performance Summary

| Treatment | Analysis | Most common side effect | Serious side effect |
|--------------|---|-------------------------------------|--|
| Liver cancer | <ul style="list-style-type: none"> 50% to 60% of patients show an improvement with respect to liver cancer progression. Overall improvement in the post-treatment survival period | Pain, fever, nausea, and tiredness. | Unintended vessel blockage or infection. Less than one out of hundred cases. |

When used as instructed, the risks from the use of HepaSphere Microspheres to treat liver cancers are low and outweighed by the clinical benefits. The benefit-risk ratio is favourable in all indications for use.

Each year, Biosphere Medical collects additional information from the scientific literature to confirm the continued safety and performance of the spheres. Biosphere Medical is also conducting a clinical study of 105 patients among 2 sites (France and Greece), to gather more data on the safety and effectiveness metastatic colorectal cancer to the liver.

6.0 Diagnostic or Therapeutic Alternatives

Surgical tumor resection or liver transplantation are other treatments options. Contact your doctor to discuss treatment options.



7.0 Suggested profile and training for users

The HepaSphere Microspheres should only be used by doctors trained in embolic procedures.

8.0 Readability Score

The readability of the patient-directed SSCP was assessed using the validated readability statistics reported by Microsoft Word for Office 365 MSO (Version 2022 Build 16.0.14931.20648) 32-bit. The statistics are summarized in Table 9. When combined with appropriate consultation with their doctor, these readability scores are considered acceptable for conveying necessary information to the patient.

Table 9. Readability Score Summary

| Statistic | Readability Score |
|-----------------------------|--------------------------|
| Flesch Reading Ease | 50.7 |
| Flesch-Kincaid Grade Level | 8.9 |
| Passive sentence percentage | 27.2% |